<?xml version="1.0" encoding="UTF-8"?>
<p id="d1e3375">SARS-CoV-2 is shown to be more sensitive to type I interferon (IFN) than SARS-CoV due to the absence of two important IFN antagonists 
 <xref rid="b53" ref-type="bibr">[53]</xref>. We examine the impact of IFN as treatment intensification with the above antiviral therapy by increasing the killing due to the innate immune response (i.e. the value of 
 <inline-formula>
  <math id="d1e3382" display="inline" altimg="si24.svg">
   <mi>ω</mi>
  </math>
 </inline-formula> in the model) by 5 folds. We find that increasing the killing by the innate immune response can largely suppress the viral replication (compare 
 <xref rid="fig8" ref-type="fig">Fig. 8</xref>A,C). Under IFN treatment, the viral load could be significantly reduced with 60% drug efficacy (lopinavir/ritonavir or remdesivir). The result suggests that early treatment with a combination of IFN and other antiviral drugs might be promising against novel coronavirus infection.
</p>
